Drug name - Sublocade
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498432 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US10592168 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US10198218 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9827241 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9782402 | INDIVIOR INC | Injectable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9272044 | INDIVIOR INC | Injectable flowable composition buprenorphine |
Jun, 2031
(8 years from now) | |
| US10558394 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US8975270 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(8 years from now) | |
| US8921387 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(9 years from now) | |
| US11000520 | INDIVIOR INC | Buprenorphine dosing regimens |
Nov, 2035
(13 years from now) | |
| US10646484 | INDIVIOR INC | Methods to treat opioid use disorder |
Jun, 2038
(15 years from now) | |
Drugs and Companies using BUPRENORPHINE ingredient
Treatment: In situ formation of solid buprenorphine composition; Treatment of moderate to severe opioid use disorder; Treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine; Treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine; Treating opioid use disorder
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/0.5ML (100MG/0.5ML) | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | Prescription |
| 300MG/1.5ML (200MG/ML) | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.